Close Menu

NEW YORK – Promega said on Thursday that it has signed a license agreement for MilliporeSigma's foundational CRISPR genome editing technology.

Under the terms of the agreement, Promega will use the CRISPR technology to create new research products for investigating endogenous biology, including products for drug development. The company is aiming to develop tools that will allow researchers to better determine physiological levels of protein expression, providing a more accurate understanding of protein behavior.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.